Revance Therapeutics (RVNC) Misses Q1 EPS by 3c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.94), $0.03 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $25.3 million versus the consensus estimate of $24.01 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• RBC bullish on Kraft Heinz, sees return to growth in 2027
• Oscar Health Inc (OSCR) PT Raised to $48 at Piper Sandler
• Wall Street on Fed rate hike: 'As hawkish as it gets'